Therapeutic Focus: Central Nervous System (CNS)

Rho has conducted over 200 CNS studies with more than 3,000 sites and 70,000 subjects. These studies cover the full range of drug development and include full service multi-protocol programs as well as tailored services for smaller projects. We have conducted CNS trials in a broad range of indications, including:

• ADHD, including analog classroom assessments
• Alzheimer's disease
• Schizophrenia
• Acute pain
• Chronic pain
• Opioid addiction
• Autism
• Bipolar disorder
• Seizures, including epilepsy
• Parkinson's disease
• Stroke
• Narcolepsy
• Mild cognitive impairment
• Stimulant abuse
• Memory impairment
• Depression/major depressive disorder

Why Choose Rho?

• More than a dozen articles in the area of CNS published in prestigious peer-reviewed journals, including The Journal of the American Medical Association (JAMA), The Lancet Neurology, The Journal of Pediatric Psychology, and The Journal of the International Neuropsychological Society
• Significant contributions to several successful 505(b)(1) NDA submissions as well as recent experience on three 505(b)(2) submissions to the FDA Division of Anesthesia, Analgesia, and Addiction Products (DAAAP)
• An outstanding track record starting up and executing CNS trials
• Excellent relationships with successful sites that will help you meet your enrollment goals
• Expertise managing and distributing Schedule II drugs
• Experience at FDA meetings handling missing data problems—a common issue in CNS trials because of study dropouts and missed assessments

Download PDF